ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression

Table 2 Autoantibody and disease features of patients with the five major autoantibodies against citrullinated protein profiles ^a

Group	n	Anti-CCP2+^b(%)	RF+ (%)	Mean ACPA level (U/ml)	Mean number of citrullinated antigens recognized (range)^c,d	(Ex-) smokers (%)^e	SE+^f(%)^d	VAS median^g
C	15	100	93	4630	6 (1 to 16)	38	93	34
D	83	88	87	1317	3 (1 to 13)	59	80	35
E	30	87	87	861	2 (0 to 5)	66	70	34
F	198	31	45	137	0 (0 to 4)	49	53	40
H	17	0	29	14	0 (0 to 1)	60	29	50

^aACPA: anticitrullinated protein antibody; CCP2: cyclic citrullinated peptide 2; RF: rheumatoid factor; SE: shared epitope; VAS: Visual Analogue Scale score. ^bMeasured using the anti-CCP2 test (CCPlus Immunoscan assay). ^cReactivity is based upon cutoff values determined with reactivity of healthy individuals with surface plasmon resonance imaging. ^dP-value < 0.01. ^eP-value = 0.278. ^fAt least one SE allele. ^gP-value = 0.958. Group differences were tested using the Kruskal-Wallis test or Pearson’s χ² test.

ISSN: 1478-6362